XBiotech's 'True Human' Antibody Xilonix Hits the Spot for Cachexia
Austin-based XBiotech Inc. is launching its first Phase III trial, for its antibody Xilonix (MABp1), after announcing Wednesday that the monoclonal antibody received fast-track designation by the FDA.
Xilonix will be tested for the treatment of cachexia, a wasting syndrome that can occur with cancer as well as other chronic diseases. In the Phase II trial that was the basis of the fast-track designation, about a third of patients responded to the antibody. And those that did not only started building muscle, but had increased survival as well.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST